Cargando…

Development of a Fragment-Based Screening Assay for the Focal Adhesion Targeting Domain Using SPR and NMR

The Focal Adhesion Targeting (FAT) domain of Focal Adhesion Kinase (FAK) is a promising drug target since FAK is overexpressed in many malignancies and promotes cancer cell metastasis. The FAT domain serves as a scaffolding protein, and its interaction with the protein paxillin localizes FAK to foca...

Descripción completa

Detalles Bibliográficos
Autores principales: Alvarado, Carlos, Stahl, Erik, Koessel, Karissa, Rivera, Andrew, Cherry, Brian R., Pulavarti, Surya V.S.R.K., Szyperski, Thomas, Cance, William, Marlowe, Timothy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6766811/
https://www.ncbi.nlm.nih.gov/pubmed/31540099
http://dx.doi.org/10.3390/molecules24183352
_version_ 1783454772956758016
author Alvarado, Carlos
Stahl, Erik
Koessel, Karissa
Rivera, Andrew
Cherry, Brian R.
Pulavarti, Surya V.S.R.K.
Szyperski, Thomas
Cance, William
Marlowe, Timothy
author_facet Alvarado, Carlos
Stahl, Erik
Koessel, Karissa
Rivera, Andrew
Cherry, Brian R.
Pulavarti, Surya V.S.R.K.
Szyperski, Thomas
Cance, William
Marlowe, Timothy
author_sort Alvarado, Carlos
collection PubMed
description The Focal Adhesion Targeting (FAT) domain of Focal Adhesion Kinase (FAK) is a promising drug target since FAK is overexpressed in many malignancies and promotes cancer cell metastasis. The FAT domain serves as a scaffolding protein, and its interaction with the protein paxillin localizes FAK to focal adhesions. Various studies have highlighted the importance of FAT-paxillin binding in tumor growth, cell invasion, and metastasis. Targeting this interaction through high-throughput screening (HTS) provides a challenge due to the large and complex binding interface. In this report, we describe a novel approach to targeting FAT through fragment-based drug discovery (FBDD). We developed two fragment-based screening assays—a primary SPR assay and a secondary heteronuclear single quantum coherence nuclear magnetic resonance (HSQC-NMR) assay. For SPR, we designed an AviTag construct, optimized SPR buffer conditions, and created mutant controls. For NMR, resonance backbone assignments of the human FAT domain were obtained for the HSQC assay. A 189-compound fragment library from Enamine was screened through our primary SPR assay to demonstrate the feasibility of a FAT-FBDD pipeline, with 19 initial hit compounds. A final total of 11 validated hits were identified after secondary screening on NMR. This screening pipeline is the first FBDD screen of the FAT domain reported and represents a valid method for further drug discovery efforts on this difficult target.
format Online
Article
Text
id pubmed-6766811
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-67668112019-10-02 Development of a Fragment-Based Screening Assay for the Focal Adhesion Targeting Domain Using SPR and NMR Alvarado, Carlos Stahl, Erik Koessel, Karissa Rivera, Andrew Cherry, Brian R. Pulavarti, Surya V.S.R.K. Szyperski, Thomas Cance, William Marlowe, Timothy Molecules Article The Focal Adhesion Targeting (FAT) domain of Focal Adhesion Kinase (FAK) is a promising drug target since FAK is overexpressed in many malignancies and promotes cancer cell metastasis. The FAT domain serves as a scaffolding protein, and its interaction with the protein paxillin localizes FAK to focal adhesions. Various studies have highlighted the importance of FAT-paxillin binding in tumor growth, cell invasion, and metastasis. Targeting this interaction through high-throughput screening (HTS) provides a challenge due to the large and complex binding interface. In this report, we describe a novel approach to targeting FAT through fragment-based drug discovery (FBDD). We developed two fragment-based screening assays—a primary SPR assay and a secondary heteronuclear single quantum coherence nuclear magnetic resonance (HSQC-NMR) assay. For SPR, we designed an AviTag construct, optimized SPR buffer conditions, and created mutant controls. For NMR, resonance backbone assignments of the human FAT domain were obtained for the HSQC assay. A 189-compound fragment library from Enamine was screened through our primary SPR assay to demonstrate the feasibility of a FAT-FBDD pipeline, with 19 initial hit compounds. A final total of 11 validated hits were identified after secondary screening on NMR. This screening pipeline is the first FBDD screen of the FAT domain reported and represents a valid method for further drug discovery efforts on this difficult target. MDPI 2019-09-14 /pmc/articles/PMC6766811/ /pubmed/31540099 http://dx.doi.org/10.3390/molecules24183352 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Alvarado, Carlos
Stahl, Erik
Koessel, Karissa
Rivera, Andrew
Cherry, Brian R.
Pulavarti, Surya V.S.R.K.
Szyperski, Thomas
Cance, William
Marlowe, Timothy
Development of a Fragment-Based Screening Assay for the Focal Adhesion Targeting Domain Using SPR and NMR
title Development of a Fragment-Based Screening Assay for the Focal Adhesion Targeting Domain Using SPR and NMR
title_full Development of a Fragment-Based Screening Assay for the Focal Adhesion Targeting Domain Using SPR and NMR
title_fullStr Development of a Fragment-Based Screening Assay for the Focal Adhesion Targeting Domain Using SPR and NMR
title_full_unstemmed Development of a Fragment-Based Screening Assay for the Focal Adhesion Targeting Domain Using SPR and NMR
title_short Development of a Fragment-Based Screening Assay for the Focal Adhesion Targeting Domain Using SPR and NMR
title_sort development of a fragment-based screening assay for the focal adhesion targeting domain using spr and nmr
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6766811/
https://www.ncbi.nlm.nih.gov/pubmed/31540099
http://dx.doi.org/10.3390/molecules24183352
work_keys_str_mv AT alvaradocarlos developmentofafragmentbasedscreeningassayforthefocaladhesiontargetingdomainusingsprandnmr
AT stahlerik developmentofafragmentbasedscreeningassayforthefocaladhesiontargetingdomainusingsprandnmr
AT koesselkarissa developmentofafragmentbasedscreeningassayforthefocaladhesiontargetingdomainusingsprandnmr
AT riveraandrew developmentofafragmentbasedscreeningassayforthefocaladhesiontargetingdomainusingsprandnmr
AT cherrybrianr developmentofafragmentbasedscreeningassayforthefocaladhesiontargetingdomainusingsprandnmr
AT pulavartisuryavsrk developmentofafragmentbasedscreeningassayforthefocaladhesiontargetingdomainusingsprandnmr
AT szyperskithomas developmentofafragmentbasedscreeningassayforthefocaladhesiontargetingdomainusingsprandnmr
AT cancewilliam developmentofafragmentbasedscreeningassayforthefocaladhesiontargetingdomainusingsprandnmr
AT marlowetimothy developmentofafragmentbasedscreeningassayforthefocaladhesiontargetingdomainusingsprandnmr